Psychemedics Corp. Files 8-K on Financials
Ticker: PMDI · Form: 8-K · Filed: Aug 13, 2024 · CIK: 806517
| Field | Detail |
|---|---|
| Company | Psychemedics Corp (PMDI) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, financials
TL;DR
Psychemedics filed an 8-K, expect financial updates soon.
AI Summary
On August 13, 2024, Psychemedics Corp. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing indicates that Psychemedics Corp. is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain information that inherently poses a high risk.
Key Players & Entities
- PSYCHEMEDICS CORP (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- August 13, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits for Psychemedics Corp.
What is the exact name of the registrant?
The exact name of the registrant is PSYCHEMEDICS CORPORATION.
In which state was Psychemedics Corp. incorporated?
Psychemedics Corp. was incorporated in Delaware.
What is the principal executive office address for Psychemedics Corp.?
The principal executive office address is 5220 Spring Valley Road, Suite 230, Dallas, Texas 75254.
What is the telephone number for Psychemedics Corp.?
The telephone number for Psychemedics Corp. is (800) 527-7424.
Filing Stats: 607 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-08-13 16:05:14
Key Financial Figures
- $0.005 — ange on which registered Common stock. $0.005 par value PMD The NASDAQ Stock Market,
Filing Documents
- f8k_081324.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 5KB
- exh991large_1.jpg (GRAPHIC) — 8KB
- 0001171843-24-004747.txt ( ) — 227KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_081324_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 13, 2024, Psychemedics Corporation (the "Company") issued a press release announcing, among other things, its results for the second quarter June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference. Limitation on Incorporation by Reference. The information furnished in this Item 2.02, including the press release attached hereto as Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed herewith: 99.1 Press release of the Company dated August 13, 2024, announcing, among other things, its results for the second quarter June 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PSYCHEMEDICS CORPORATION Date: August 13, 2024 By: /s/ Brian Hullinger Brian Hullinger President and Chief Executive Officer